期刊
JOURNAL OF IMMUNOLOGICAL METHODS
卷 315, 期 1-2, 页码 121-132出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jim.2006.07.015
关键词
ELISpot; HIV-1 vaccine; permutation test; positivity; T lymphocytes
资金
- NIAID NIH HHS [P30 AI27757, R01 AI47086, R37 AI35605, R01 AI48017, R01 AI65328, U01 AI46725, P01 AI57005] Funding Source: Medline
The enzyme-linked immunospot (ELISpot) assay is one of the leading technologies used to measure cellular responses in many settings including HIV vaccine clinical trials. HIV-1-specific effector T lymphocyte responses are considered necessary in the control of infection. Accurate measurement and summary of cellular immune responses are critical to HIV research. ELISpot assay readout is often dichotomized into positive/negative responses according to some pre-specified criteria. Given the increase in the number of replicates used for each stimulation with current assay configurations in the HIV Vaccine Trials Network (HVTN) laboratories, a new approach is now possible. We propose an objective criteria based on a hypothesis-driven method that controls the false positive rate while maintaining sensitivity to each of the antigen-specific responses under study. The new approach is compared to other commonly employed criteria using real and simulated data. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据